



Correction to: ^{225}Ac -PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study

Mike Sathekge¹  · Frank Bruchertseifer² · Otto Knoesen³ · Florette Reyneke¹ · Ismaheel Lawal¹ · Thabo Lengana¹ · Cindy Davis¹ · Johnny Mahapane¹ · Ceceila Corbett¹ · Mariza Vorster¹ · Alfred Morgenstern^{1,2}

Published online: 26 June 2019

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Correction to: European Journal of Nuclear Medicine and Molecular Imaging
<https://doi.org/10.1007/s00259-018-4167-0>

The author of this article wanted to change the ethical approval statement of the originally published version of this article. Correct statement is indicated below.

Ethical approval We obtained a section 21 approval from the South African Health Products Regulatory Authority for compassionate use of ^{225}Ac -PSMA-617 and all patients treated gave a written informed consent.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s00259-018-4167-0>

✉ Mike Sathekge
mike.sathekge@up.ac.za

¹ Department of Nuclear Medicine, Steve Biko Academic Hospital, University of Pretoria, Private Bag X169, Pretoria 0001, South Africa

² European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany

³ Nuclear Technology Products (NTP), Pelindaba, South Africa